Nitecapone is a selective inhibitor of the enzyme catechol-O-methyltransferase (COMT), classified as an antiparkinsonian agent used to treat Parkinson's disease by prolonging the half-life of dopamine… Read more
Nitecapone is a selective inhibitor of the enzyme catechol-O-methyltransferase (COMT), classified as an antiparkinsonian agent used to treat Parkinson's disease by prolonging the half-life of dopamine within the brain. The compounds listed in this category, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled standards such as Nitecapone-13C5, are essential for rigorous analytical testing and quality control. Pharmaceutical laboratories utilize these high-quality reference standards to perform accurate impurity profiling, ensuring compliance with regulatory standards throughout the development of the active pharmaceutical ingredient. Stable isotope-labelled compounds serve as critical internal standards for mass spectrometry-based assays, facilitating precise quantification during method validation and ongoing stability studies. Accessing these diverse, characterized compounds supports the consistent monitoring of drug purity and the reliable detection of degradation products across the lifecycle of the pharmaceutical product.